spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  asparaginase 

 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2014
Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Feb 2012
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2006
Enzon Pharmaceuticals Announces Advancements in Its Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jul 2006
FDA Approves Enzon's Oncaspar(R) for First-Line Use in Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2006
Enzon Initiates Clinical Program for ONCASPAR(R)
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
asparaginase
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.